Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: Preliminary data

Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: Preliminary data

AIM: To evaluate the efficacy of rituximab (RT) in cryoglobulinemic vasculitis (CGV) and MALT lymphomas of the parotid gland (PG) in patients with Sjögren's disease (SD). /MATERIAL AND METHODS: RT therapy was performed in 13 patients with SD and CGV and in 17 with SD and PG MALT lymphoma. Eleve...

Full description

Bibliographic Details
Main Authors: O A Logvinenko, V I Vasil'ev, S Kh Sedyshev, T N Safonova, E B Rodionova, N V Kokosadze, E N Aleksandrova, M V Cherkasova, S G Radenska-Lopovok, E L Nasonov
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2012-12-01
Series:Терапевтический архив
Subjects:
rituximab
sjögren's disease
malt lymphomas of the parotid gland
Online Access:https://ter-arkhiv.ru/0040-3660/article/view/31174

Similar Items

Similar Items